Management of Pneumocystis pneumonia in patients with inflammatory disorders

Expert Review of Anti-Infective Therapy

Volumn 3, Issue 3, 2005, Pages 435-444

  Roblot, France ^a  

^a POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

CD4+ T cell count; Connective tissue diseases; Immunosuppresive drugs; Inflammatory disorders; PCP management; PCP prophylaxis; Pneumocystis jirovecii

Indexed keywords

ATOVAQUONE; AZATHIOPRINE; CD4 ANTIGEN; CLINDAMYCIN; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC AGENT; DAPSONE; FOLINIC ACID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; PENTAMIDINE; PREDNISOLONE; PRIMAQUINE; PYRIMETHAMINE; TRIMETHOPRIM; TRIMETREXATE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

AMINOTRANSFERASE BLOOD LEVEL; DESQUAMATION; DIABETES MELLITUS; DIARRHEA; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; ERYTHEMA MULTIFORME; FEVER; HEPATITIS; HUMAN; HYPOGLYCEMIA; HYPOTENSION; IMMUNOFLUORESCENCE TEST; INFLAMMATORY DISEASE; KIDNEY DYSFUNCTION; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; NAUSEA; NEPHRITIS; NEPHROTOXICITY; NEUTROPENIA; OPPORTUNISTIC INFECTION; PANCREATITIS; PANCYTOPENIA; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; POLYMERASE CHAIN REACTION; PROGNOSIS; RASH; REVIEW; RISK FACTOR; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; VOMITING; WEGENER GRANULOMATOSIS;

ANTIFUNGAL AGENTS; HUMANS; IMMUNOCOMPROMISED HOST; INFLAMMATION; PNEUMONIA, PNEUMOCYSTIS;

EID: 21044445191     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.3.3.435     Document Type: Review

References (76)

1. Stringer JR, Beard CB, Miller RF, Wakefield AE. A new name (Pneumocystis jirovecii) for Pneumocystis from humans. Emerg. Infect. Dis. 8, 891-896 (2002).
2. Morris A, Lundgren JD, Masur H et al. Current epidemiology of Pneumocystis pneumonia. Emerg. Infect. Dis. 10, 1713-1720 (2004).
3. Sepkowitz KA, Brown AE, Armstrong D. Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome: more patients, same risk. Arch. Intern. Med. 155, 1125-1128 (1995).
4. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin. Proc. 71, 5-13 (1996).
5. Raychaudhuri SP, Siu S. Pneumocystis carinii pneumonia in patients receiving immunosuppressive drugs for dermatological diseases. Br. J. Dermatol. 141, 528-530 (1999).
6. Roblot F, Godet C, Le Moal G et al. Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients. Eur. J. Clin. Microbiol. Infect. Dis. 21, 523-531 (2002).
7. Ward MM, Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum. 4, 780-789 (1999).
8. Porges AJ, Beattie SL, Ritchlin C, Kimberly RP, Christian CL. Patients with systemic lupus erythematosus at risk for Pneumocystis carinii pneumonia. J. Rheumatol. 19, 1191-1194 (1992).
9. Jarrousse B, Guillevin L, Bindi P et al. Increased risk of Pneumocystis carinii pneumonia in patients with Wegener's granulomatosis. Clin. Exp. Rheumatol. 11, 615-621 (1993).
10. Godeau B, Coutant-Perronne V, Le Thi Huong D et al. Pneumocystis carinii pneumonia in the course of connective tissue diseases: report of 34 cases. J. Rheumatol. 21, 246-251 (1994).
11. Ognibene FP, Shelhamer JH, Hoffman GS et al. Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis. Am. J. Respir. Crit. Care Med. 151, 795-799 (1995).
12. Gerrard JG. Pneumocystis carinii pneumonia in HIV-negative immunocompromised adults. Med. J. Austr. 162, 233-235 (1995).
13. Stenger AA, Houtman PM, Bruyn GA, Eggink HF, Pasma HR. Pneumocystis carinii pneumonia associated with low dose methotrexate treatment for rheumatoid arthritis. Scand. J. Rheumatol. 23, 51-53 (1994).
14. Krebs S, Gibbons RB. Low-dose methotrexate as a risk factor for Pneumocystis carinii pneumonia. Mil. Med. 161, 56-60 (1996).
15. + T-lymphocytopenia. Eur. Respir. J. 10, 1184-1186 (1997).
16. Kadoya A, Okada J, Iikuni Y, Kondo H. Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis/dermatomyositis or systemic lupus erythematosus. J. Rheumatol. 23, 1186-1188 (1996).
17. Bachelez H, Schremmer B, Cadranel J et al. Fulminant Pneumocystis carinii pneumonia in 4 patients with dermatomyositis. Arch. Intern. Med. 157, 1501-1503 (1997).
18. Sowden E, Carmichael AJ. Autoimmune inflammatory disorders, systemic corticosteroids and Pneumocystis pneumonia: a strategy for prevention. BMC Infect. Dis. 4, 42 (2004).
19. Scott AM, Myers GA, Harms BA. Pneumocystis carinii pneumonia postrestorative proctocolectomy for ulcerative colitis: a role for perioperative prophylaxis in the cyclosporin era? Report of a case and review of the literature. Dis. Colon Rectum 40, 973-976 (1997).
20. Katchatourian M, Seaton TL. An unusual complication of immunosuppressive therapy in inflammatory bowel disease. Am. J. Gastroenterol. 92, 1558-1560 (1997).
21. Seddik M, Meliez H, Seguy D, Viget N, Cortot A, Colombel JF. Pneumocystis jirovecii (carinii) pneumonia following initiation of infliximab and azathioprine therapy in a patient with Crohn's disease. Inflamm. Bowel Dis. 10, 436-437 (2004).
22. Velayos FS, Sandborn WJ. Pneumocystis carinii pneumonia during maintenance antitumor necrosis factor-alpha therapy with infliximab for Crohn's disease. Inflamm. Bowel Dis. 10, 657-660 (2004).
23. Morrison LH. Therapy of refractory pemphigus vulgaris with monoclonal antiCD20 antibody (rituximab). J. Am. Acad. Dermatol. 51, 817-819 (2004).
24. Crayton HE, Sundstrom WR. Pneumocystis carinii pneumonia following corticosteroid therapy for giant cell arteritis. Wis. Med. J. 90, 170-171 (1991).
25. Hedderwick SA, Bonilla HF, Bradley SF, Kauffman CA. Opportunistic infections in patients with temporal arteritis treated with corticosteroids. J. Am. Geriatr. Soc. 45, 334-337 (1997).
26. Saito K, Nakayamada S, Nakano K et al. Detection of Pneumocystis carinii by DNA amplification in patients with connective tissue diseases: re-evaluation of clinical features of Pneumocystis carinii pneumonia in rheumatic diseases. Rheumatology 43, 479-485 (2004).
27. Takenata R, Okada H, Mizuno M. Pneumocystis carinii pneumonia in patients with ulcerative colitis. J. Gastroenterol. 39, 1114-1119 (2004).
28. Tai TL, O'Rourke KP, McWeeney M, Burke CM, Sheehan K, Barry M. Pneumocystis carinii pneumonia following a second infusion of infliximab. Rheumatology 41, 951-952 (2002).
29. Thomas CF, Limper AH. Pneumocystis pneumonia. N. Engl. J. Med. 350, 2487-2498 (2004).
30. Baumgartner RE, Durant PJ, van Gessel Y et al. Evidence for the requirement of T-cell costimulation in the pathogenesis of natural Pneumocystis carinii pulmonary infection. Microbial. Pathog. 33, 193-201 (2002).
31. Godeau B, Mainardi JL, Roudot-Thoraval F et al. Factors associated with Pneumocystis carinii pneumonia in Wegener's granulomatosis. Ann. Rheum. Dis. 54, 991-994 (1995).
32. Viguier M, Fouere S, de la Salmoniere P et al. Peripheral blood lymphocyte subset counts in patients with dermatomyositis: clinical correlations and changes following therapy. Medicine 82, 82-86 (2003).
33. + T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection. Chest 118, 712-720 (2000).
34. + T-cell counts. Clin. Infect. Dis. 29, 1331-1332 (1999).
35. Helweg-Larsen J, Jensen JS, Benfield T, Svendsen UG, Lundgren JD, Lundgren B. Diagnostic use of PCR for detection of Pneumocystis carinii in oral wash samples. J. Clin. Microbiol. 36, 2068-2072 (1998).
36. Larsen HH, Huang L, Kovacs JA et al. A prospective, blinded study of quantitative touch-down polymerase chain reaction using oral-wash samples for diagnosis of Pneumocystis pneumonia in HIV-infected patients. J. Infect. Dis. 189, 1679-1683 (2004).
37. Pinlaor S, Mootsikapun P, Pinlaor P et al. PCR diagnosis of Pneumocystis carinii on sputum and bronchoalveolar lavage samples in immunocompromised patients. Parasitol. Res. 94, 213-218 (2004).
38. Flori P, Bellete B, Durand F et al. Comparison between real-time PCR, conventional PCR and different staining techniques for diagnosing Pneumocystis jiroveci pneumonia from bronchoalveolar lavage specimens. J. Med. Microbiol. 53, 603-607 (2004).
39. Daly KR, Koch J, Levin L, Walzer PD. Enzyme-linked immunosorbent assay and serologic responses to Pneumocystis jiroveci. Emerg. Infect. Dis. 10, 848-854 (2004).
40. Skelly M, Hoffman J, Fabbri M, Holzman RS, Clarkson Jr AB, Merali S. S-adenosylmethionine concentrations in diagnosis of Pneumocystis carinii pneumonia. Lancet 361, 1267-1268 (2003).
41. Sepkowitz KA. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin. Infect. Dis. 34, 1098-1107 (2002).
42. Masur H, Kaplan JE, Holmes KK. Guidelines for preventing opportunistic infections among HIV- infected persons - 2002. Recommendations of the Public Health Service and the Infectious Diseases Society of America. Ann. Intern. Med. 137, 435-478 (2002).
43. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 33, 139-144 (2001).
44. Gordon SM, LaRosa SP, Kalmadi S et al. Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued? Clin. Infect. Dis. 28, 240-246 (1999).
45. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. IV: long-term management of the transplant recipient. IV. 7 infections. Pneumocystis carinii pneumonia. Nephrol. Dial. Transplant. 17, 36-39 (2002).
46. Mansharamani NG, Garland R, Delaney D, Koziel H. Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995. Comparison of HIV-associated cases to other immunocompromised states. Chest 118, 704-711 (2000).
47. Fishman JA. Prevention of infection due to Pneumocystis carinii. Antimicrob. Agents Chemother. 42, 995-1004 (1998).
48. Chung JB, Armstrong K, Schwartz JS, Albert D. Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegener's granulomatosis undergoing immunosuppressive therapy. Arthritis Rheum. 43, 1841-1848 (2000).
49. Ioannidis JPA, Cappelleri JC, Skolnik PR, Lau J, Sacks HS. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylaxis regimens. Arch. Intern. Med. 156, 177-188 (1996).
50. Langford CA, Tatar-Williams C, Barron KS, Sneller MC. Use of cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am. J. Med. 114, 463-469 (2003).
51. Arend SM, van't Wout JW. Prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients. As long as the pros outweigh the cons. Clin. Infect. Dis. 28, 247-249 (1999).
52. Armstrong W, Meshnick S, Kazanjian P. Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in immunocompromised patients. Microb. Infect. 2, 61-67 (2000).
53. Ma L, Borio L, Masur H, Kovacs JA. Pneumocystis carinii dihydropteroate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use. J. Infect. Dis. 180, 1969-1978 (1999).
54. Meneau I, Sanglard D, Bille J, Hauser PM. Pneumocystis jiroveci dihydropteroate synthase polymorphism and resistance to sulfadoxine and sulfanilamide in Saccharomyces cerevisiae. Antimicrob. Agents Chemother. 48, 2610-2616 (2004).
55. Nahimana A, Rabodonirina M, Zanetti G et al. Association between a specific Pneumocystis jiroveci dihydropteroate synthase mutation and failure of pyrimethamine-sulfadoxine prophylaxis in human immunodeficiency virus-positive and negative patients. J. Infect. Dis. 188, 1017-1023 (2003).
56. Nahimana A, Rabodonirina M, Bille J, Francioli P, Hauser PM. Mutations of Pneumocystis jiroveci dihydrofolate reductase with failure of prophylaxis. Antimicrob. Agents Chemother. 48, 4301-4305 (2004).
57. Cushion MT. Pneumocystis: unravelling the cloak of obscurity. Trends Microbiol. 12, 243-249 (2004).
58. Huang L, Crothers K, Atzori C et al. Dihydropteroate synthase gene mutations in Pneumocystis associated with resistance. Emerg. Infect. Dis. 10, 1721-1728 (2004).
59. Bozette SA, Sattler FR, Chiu J et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis pneumonia in the acquired immunodeficiency syndrome. N. Engl. J. Med. 323, 1451-1457 (1990).
60. El-Sadr WM, Murphy RL, McCabe Yurik T et al. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfatethoxazole or both. N. Engl. J. Med. 339, 1889-1895 (1998).
61. Rodriguez M, Sifri CD, Fishman JA. Failure of low-dose atovaquone prophylaxis against Pneumocystis jiroveci infection in transplant recipients. Clin. Infect. Dis. 38, E76-E78 (2004).
62. Kessl JJ, Hill P, Lange BB, Meshnick SR, Meunier B, Trumpower BL. Molecular basis for atovaquone resistance in Pneumocystis jiroveci modeled in the cytochrome bc1 complex of Saccharomyces cerevisiae. J. Biol. Chem. 279, 2817-2824 (2004).
63. Marras TK, Sanders K, Lipton JH, Messner HA, Conly J, Chan CK. Aerosolized pentamidine prophylaxis for Pneumocystis carinii pneumonia after allogenic marrow transplantation. Transplant. Infect. Dis. 4, 66-74 (2002).
64. Saukkonen K, Garland R, Koziel H. Aerosolized pentamidine as alternative primary prophylaxis against Pneumocystis carinii pneumonia in adult hepatic and renal transplant recipients. Chest 109, 1250-1255 (1996).
65. Konishi M, Yoshimoto E, Takahashi K et al. Aerosolized pentamidine prophylaxis against AIDS-related Pneumocystis carinii pneumonia and its short- and long-term effects on pulmonary function in Japanese. J. Infect. Chemother. 9, 178-182 (2003).
66. Theus SA, Smulian AG, Steele P, Linke MJ, Walzer PD. Immunisation with the major glycoprotein of Pneumocystis carinii elicits a protective response. Vaccine 16, 1149-1157 (1998).
67. Fishman JA. Treatment of infection due to Pneumocystis carinii. Antimicrob. Agents Chemother. 42, 1309-1314 (1998).
68. Hughes WT, LaFon S, Scott J, Masur H. Adverse events associated with trimethoprim-sulfamethoxazole and atovaquone during the treatment of AIDS-related Pneumocystis carinii pneumonia. J. Infect. Dis. 171, 1295-1301 (1995).
69. Sepkowitz KA. Pneumocystis carinii pneumonia in patients without AIDS. Clin. Infect. Dis. 17, S416-S422 (1993).
70. Smego JR, Nagar S, Maloba B, Popara M. A meta-analysis of salvage therapy for Pneumocystis carinii pneumonia. Arch. Intern. Med. 161, 1529-1533 (2001).
71. Cushion MT, Walzer PD, Collins MS et al. Highly active anti-Pneumocystis carinii compounds in a library of novel piperazine-linked bisbenzamidines and related compounds. Antimicrob. Agents Chemother. 48, 4209-4216 (2004).
72. Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adults' non-HIV Pneumocystis carinii pneumonia. Chest 113, 1215-1224 (1998).
73. Delclaux C, Zahar JR, Amraoui G et al. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in non-human immunodeficiency virus-infected patients: a retrospective study of 31 patients. Clin. Infect. Dis. 29, 670-672 (1999).
74. Zahar JR, Robin M, Azoulay E, Fieux F, Nitenberg G, Schlemmer B. Pneumocystis carinii pneumonia in critically ill patients with malignancy: a descriptive study. Clin. Infect. Dis. 35, 929-934 (2002).
75. Roblot F, Le Moal G, Godet C et al. Pneumocystis carinii pneumonia in patients with hematologic malignancies: a descriptive study. J. Infect. 47, 19-27 (2003).
76. Rabodonirina M, Vanhems P. Couray-Targe S et al. Molecular evidence of interhuman transmission of Pneumocystis pneumonia among renal transplant recipients hospitalized with HIV infected patients. Emerg. Infect. Dis. 10, 1766-1773 (2004).